scholarly journals Comorbidity of atopic bronchial asthma and food allergy in adults

2021 ◽  
Author(s):  
Y. Zhorina ◽  
G. Ignatov ◽  
O. Abramovskikh ◽  
I. Zherebcova
Keyword(s):  
Food Allergy ◽  
Bronchial Asthma ◽  
Clinical Manifestations ◽  
Significant Risk ◽  
Atopic Asthma ◽  
Food Allergies ◽  
Atopic Bronchial Asthma ◽  
Increased Risk ◽  
Wide Range ◽  
Emergency Drugs

Adult patients with atopic bronchial asthma are susceptible to food allergy, in more than one third of cases, while asthma is a risk factor for severe life-threatening factors. The aim of the study was to determine the prevalence and relationship of food allergies with atopic bronchial asthma in adults living in Chelyabinsk. Materials and methods. An analysis of 313 outpatient case histories of patients with atopic bronchial asthma over the age of 18 was performed. Results. The presence of food allergy was a factor in the earlier onset of atopic bronchial asthma, which is consistent with the concept of comorbidity of these diseases. Patients with seasonal allergic rhinitis and pollen sensitization have an increased risk of developing food allergies (OR – 2.075 [1.27- 3.39]), p=0,004. The overall incidence of oral allergic syndrome among all patients with atopic asthma and plant sensitization was 33% [28; 37]. Plant products (fruits, honey, nuts) were the cause of food allergic reactions in 87% [80; 92] of adult cases. The main clinical manifestations were: oral allergic syndrome, urticaria, angioedema, shortness of breath. Sensitization to pollen of trees, grasses and weeds approximately equally increases the risk of developing an oral allergic syndrome, upon sensitization to tree pollen (OR – 3.08 [2.32-4.25]), to grass pollen (OR – 3.5 [2.23-5.61]), to weed pollen (OR – 2.86 [2.02-4.03]). The combination of several types of pollen sensitization increases by 4 times the risk of developing oral allergic syndrome to a wide range of foods. Conclusion. Data on the causes and clinical manifestations of food allergies in combination with bronchial asthma have been obtained. The notion of a significant risk of developing dangerous clinical manifestations of food allergy in patients with atopic bronchial asthma will make it possible to reasonably prescribe emergency drugs for independent use.

scholarly journals THE EFFECT OF MAGNETO-LASER THERAPY ON THE PHENOTYPE OF BASOPHILS IN CHILDREN WITH ATOPIC ASTHMA

2019 ◽  
Vol 29 (2) ◽  
pp. 35-38
Author(s):  
Elena Asiryn ◽  
Pavel Novikov ◽  
Volha Matsiushchanka ◽  
Nadiezhda Titova ◽  
Lukas Vaidelys ◽  
...  
Keyword(s):  
Laser Therapy ◽  
Bronchial Asthma ◽  
Inhaled Corticosteroids ◽  
Atopic Asthma ◽  
Relative Level ◽  
Atopic Bronchial Asthma ◽  
Significant Difference ◽  
Group A ◽  
The Absolute ◽  
Group B

In recent years there has been growing evidence to suggest a major role of basophils alongside eosinophils and mast cells in allergic inflammation. The aim of this study was to analyze the dynamics of the basophil phenotypes after the use of magneto-la-ser therapy in children with atopic bronchial asthma. Materials and methods. A total of 66 children with mild persistent atopic bronchial asthma (aged 6 to 18 years old) were examined. Group A included 34 children who received magneto-laser therapy together with basic asthma treatment (low dose of inhaled corticosteroids). Group B included 32 children who received only basic asthma therapy. The level of CD203с + , CD203с + CD63 + , CD203с + IgE + basophils was determined in peripheral blood in the beginning of the study, after 2 weeks and after 3 months. Results. A statistically significant decrease in the absolute levels of CD203с+CD63+ and CD203с + IgE + basophils and in the relative level of CD203с + IgE + among all CD203с + basophils was determined in group A after magneto-laser therapy. The comparison of group A and group B indices revealed a significant difference between the relative level of CD203с + IgE + basophils after 12-15 days from the beginning of the study. This indicator was significantly lower in group A than in group B (p<0.05). The absolute level of CD203с + IgE + basophils was significantly lower in group A in comparison with group B after 82-90 days (p<0.05). Conclusions. Magneto-laser therapy can change the phenotype of basophils in children with atopic bronchial asthma, causing suppression of proallergic pa-rameters. Considering these results there is reason to believe, that it is possible to use this method as an additional immunocorrective treatment in patients with basophilic phenotype of atopic asthma.

scholarly journals GLUCOSAMINYLMURAMYL DIPEPTIDE IN THE THERAPY OF PATIENTS WITH ATOPIC BRONCHIAL ASTHMA AND CLINICAL MANIFESTATIONS OF THE SYNDROME OF SECONDARY IMMUNE DEFICIENCY

2017 ◽  
Vol 14 (6) ◽  
pp. 91-97
Author(s):  
O V Skorokhodkina ◽  
A V Luntsov
Keyword(s):  
Respiratory Tract ◽  
Bronchial Asthma ◽  
Clinical Manifestations ◽  
Atopic Bronchial Asthma ◽  
Immune Parameters ◽  
Group I ◽  
Complex Therapy ◽  
Asthma Patients ◽  
Group Ii ◽  
Tract Infections

Background. Glucosaminylmuramyl dipeptide (likopid) is a selective NOD2 receptor agonist, its ability to activate phagocytes proves its use in infectious manifestations in asthma patients. Its influence on the adaptive immunity, was studied. The aim of the study was to evaluate the effectiveness of likopid in patients with atopic bronchial asthma and recurrent infections of the respiratory tract. Materials and methods. 44 patients with uncontrolled atopic bronchial asthma with recurrent respiratory tract infections were examined. Patients of group I received likopid 10 mg orally once a day during 10 days additionally to the complex therapy. Patients of group II received only complex therapy without likopid. The immune parameters, disease control parameters, frequency of exacerbations and spirography data in patients of two groups before the treatment and after 10 days, 1 and 3 months were assessed. Results. Both I and II group patients (91,6%) showed similar deviations of the immune status parameters in general, a depression of the functional activity of phagocytes was noted in 83,3% of cases. Patients of group I were characterized by the achievement of better asthma control in 1 month of treatment, while the frequency of asthma exacerbations required revision of therapy was lower in patients of group I than in patients of group II (8,3% and 45%, respectively, p

scholarly journals Association of promoter region polymorhism of the tnfб gene with the development of atopic bronchial asthma

2005 ◽  
Vol 3 (3) ◽  
pp. 33-37
Author(s):  
Julia V Ostankova ◽  
Tatyana E Ivashchenko ◽  
Ludmila A Zhelenina ◽  
Vladislav S Baranov
Keyword(s):  
Bronchial Asthma ◽  
Rflp Analysis ◽  
Population Group ◽  
Asthmatic Patients ◽  
Atopic Bronchial Asthma ◽  
Reversible Airway Obstruction ◽  
Increased Risk ◽  
Significant Difference ◽  
Pcr Rflp ◽  
Tnfa Gene

Atopic bronchial asthma (ABA) is a complex genetic disease characterized by increased airway responsiveness to a variety of stimuli, reversible airway obstruction, and airway inflammation. The genetic polymorphisms -238 A/G and -308 A/G of the TNFA gene were studied by PCR-RFLP analysis in the group of asthmatic patients with age of manifestation before 18 years (83) and the population group (117). According to obtained data the frequency of -238A allele of the TNFA gene was significantly lower in the group of patients with ABA (1,2%) as compared to the population group (5,6%). The analysis of distribution of the G -308A polymorphism of the TNFA gene revealed significant increase of the frequency of -308A allele in the patients with ABA (9,0%) as compared to the population (4,0%). According to odds ratio the careers of -308A allele of the TNFA gene have 2-fold increased risk of the development of ABA (OR = 2,48; CI: 1,06-5,82). The frequency of -308A allele of the TNFA gene in the group of patients was significantly higher in women (14,8 %) as compared to men (2,6 %, p = 0,0064, df = 1). After comparing the distribution of genotypes of -238 and -308 polymorphisms of the TNFA gene together significant difference between patients with ABA and population was observed. Combined genotype -238A/G + -308G/G of the TNFA gene associated with the lowest level of gene expression resulted in considerable decrease of ABA risk (OR = 0,097). Different hypotheses of the role of polymorphic variants of the TNFA gene in pathogenesis of ABA were discussed.

scholarly journals Acute Hypocalcemia and Metabolic Alkalosis in Children on Cation-Exchange Resin Therapy

2017 ◽  
Vol 2017 ◽  
pp. 1-5
Author(s):  
Aadil Kakajiwala ◽  
Kevin T. Barton ◽  
Elisha Rampolla ◽  
Christine Breen ◽  
Madhura Pradhan
Keyword(s):  
Metabolic Alkalosis ◽  
Calcium Supplementation ◽  
Cation Exchange Resin ◽  
Clinical Manifestations ◽  
Chelating Agent ◽  
Exchange Capacity ◽  
Sodium Polystyrene Sulfonate ◽  
Close Monitoring ◽  
Increased Risk ◽  
Wide Range

Background. Sodium polystyrene sulfonate (SPS) is a chelating agent used for the treatment of hyperkalemia. SPS has a wide range of exchange capacity requiring close monitoring of serum electrolytes. We observed two patients who developed acute hypocalcemia and increased metabolic alkalosis after initiating SPS therapy. We report these cases to draw attention to the potential risk of this medication in pediatric patients. Case Diagnosis/Treatment. Two children with chronic kidney disease on dialysis were started on SPS for hyperkalemia. Within a week after initiation of the medication, both patients developed hypocalcemia on routine labs without overt clinical manifestations. The hypocalcemia was rapidly corrected with oral supplementation and discontinuation of SPS. Conclusions. Severe hypocalcemia can develop after SPS therapy. The metabolic alkalosis in these patients associated with the hypocalcemia put them at increased risk for complications. Hence, careful attention must be paid to the state of calcium metabolism in all patients receiving SPS. Often calcium supplementation is required to maintain normal calcium levels.

scholarly journals ECONOMIC ASPECTS OF APPLICATION OF THE RUSSIAN BIOSIMILAR OMALIZUMAB IN PATIENTS WITH ATOPIC BRONCHIAL ASTHMA OF MODERATE TO SEVERE CLINICAL COURSES

2021 ◽  
Vol 9 (3) ◽  
pp. 235-248
Author(s):  
V. S. Krysanova ◽  
E. D. Ermolaeva ◽  
T. N. Ermolaeva ◽  
M. V. Davydovskaya ◽  
K. A. Kokushkin
Keyword(s):  
Monoclonal Antibodies ◽  
Medical Care ◽  
Bronchial Asthma ◽  
Impact Analysis ◽  
Budget Impact ◽  
Budget Impact Analysis ◽  
Adult Patients ◽  
Atopic Asthma ◽  
Atopic Bronchial Asthma ◽  
Number Of Patients

A certain success in the treatment of bronchial asthma is associated with the introduction of monoclonal antibodies into the treatment process. They made it possible to improve the control of the disease. A number of original genetically engineered biological drugs, such as benralizumab, reslizumab, dupilumab, mepolizumab and omalizumab, are currently registered in Russia. In 2020, this list was supplemented by the first Russian biosimilar drug omalizumab – Genolar® (JSC Generium, Russia). High rates of the development of modern medicine are closely related to the use of biosimilars. The prescription of biosimilars today often makes it possible to provide a larger number of patients with modern drugs at lower costs.The aim of the study was a comprehensive pharmacoeconomic assessment of the application of the domestic biosimilar drug omalizumab in the treatment of patients suffering from moderate and severe atopic bronchial asthma.Materials and methods. At the first stage, an information search in the available databases (Cochrane Library, MedLine, Embase, eLIBRARY) was carried out. According to the results obtained, a meta-analysis (Agache I. et al.) was found out; within its framework, the efficacy and safety of the use of several monoclonal antibodies was assessed. Dupilumab was chosen as the reference drug. Pharmacoeconomic analyses were carried out using a “Cost-Minimization Analysis” (CMA) and a “Budget Impact Analysis” (BIA). Taking into account various options of bronchial asthma, the developed algorithm for providing medical care to adult patients with atopic asthma made it possible to assess the costs, including direct medical and indirect costs.Results. The cost analysis demonstrated the advantage of using the Russian biosimilar omalizumab in patients with atopic asthma compared to dupilumab due to financial savings of up to 40%. The Budget Impact Analysis showed that the use of the domestic biosimilar omalizumab, even taking into account the annual increase in the number of patients (8%), will save up to 109,641,409.64 rubles (or 3%) compared to the current practice.Conclusion. The use of the domestic biosimilar omalizumab in patients with moderate to severe atopic bronchial asthma is a clinically effective and economically justified approach to organizing medical care for adult patients in Russia.

scholarly journals Initial vegetative tone in mild atopic asthma in children

2021 ◽  
Vol 12 (2) ◽  
pp. 13-18
Author(s):  
Vladimir N. Buryak ◽  
Tatyana I. Antonova ◽  
Maria V. Dudko ◽  
Inna V. Malysheva ◽  
Kirill K. Shepelenko
Keyword(s):  
Nervous System ◽  
Autonomic Nervous System ◽  
Bronchial Asthma ◽  
The Body ◽  
Atopic Asthma ◽  
World Health ◽  
Control Group ◽  
Healthy Children ◽  
Autonomic Nervous ◽  
Atopic Bronchial Asthma

Background. In most industrialized countries, allergic diseases affect up to 20% of the population. This pathology belongs to the most common in children: according to the World Health Organization, more than 15% of the world's child population suffers from it. In recent years, there has been a significant increase in the frequency and more severe course of these diseases, in connection with which they are considered in modern society as a major medical and social problem. Thus, the prevalence of bronchial asthma, according to domestic and foreign authors, ranges from 0.2 to 8.1%. Purpose. In order to clarify the role of the autonomic nervous system in the genesis of the mild course of atopic bronchial asthma in childhood, the features of the interaction of the sympathetic and parasympathetic divisions of the autonomic nervous system in the examined children were clarified. Materials and methods. 126 children aged 10 to 14 years were examined. Atopic bronchial asthma was diagnosed in 91 children. At the same time, 61 of them were diagnosed with an intermittent course, 30 a mild persistent course of the disease. The control group consisted of 35 healthy children also aged 10 to 14 years. Complaints, anamnesis data were studied in all children, an objective and generally accepted laboratory and instrumental examination was carried out. All examined children underwent daily monitoring of the electrocardiogram, according to the results of which, based on the analysis of time and frequency indicators of heart rate variability, a variant of the initial autonomic tone was established. Results. In children with atopic bronchial asthma, both with intermittent and mild persistent course, an absolute or relative dominance of sympathetic influences was revealed against the background of varying degrees of decrease in parasympathetic activity, which was interpreted as a compensatory reaction of the body in response to chronic allergic inflammation.

scholarly journals The efficacy of the symptomatic therapy of the non-atopic bronchial asthma attack in schoolchildren

2014 ◽  
Vol 18 (1 (69)) ◽  
Author(s):  
S. I. Sazhyn
Keyword(s):  
Bronchial Asthma ◽  
Symptomatic Treatment ◽  
Atopic Asthma ◽  
Bronchial Obstruction ◽  
Symptomatic Therapy ◽  
Asthma Phenotype ◽  
Atopic Bronchial Asthma ◽  
Asthma Attack ◽  
Hospitalization Period ◽  
Comparison Groups

The effectiveness of symptomatic treatment of bronchial asthma in children has been studied. It has been found that patients with non-atopic asthma phenotype were characterized by more severe bronchial obstruction during exacerbations compared with atopic patients. Children afflicted with nonatopic phenotype of the disease were characterized by more pronounced signs of airway obstruction during the whole hospitalization period despite the identical standard regimens in the comparison groups.

The Montelukast Therapy in Asthmatic Children with and without Food Allergy: Does It Make Any Difference?

2021 ◽  
pp. 1-10
Author(s):  
Umit Murat Sahiner ◽  
Ebru Arik Yilmaz ◽  
Sara Fontanella ◽  
Sadia Haider ◽  
Ozge Soyer ◽  
...  
Keyword(s):  
Food Allergy ◽  
Exhaled Breath Condensate ◽  
Food Allergies ◽  
Exhaled Breath ◽  
Double Blind ◽  
Asthma Morbidity ◽  
Asthmatic Children ◽  
Increased Risk ◽  
Significant Difference ◽  
Children With Asthma

<b><i>Introduction:</i></b> Children with food allergy are at increased risk for asthma and asthma morbidity. Since leukotrienes are implicated in the pathogenesis of both asthma and probably in food allergies, we hypothesized that asthmatic children with concomitant food allergy may have a favorable response to antileukotriene treatment. <b><i>Methods:</i></b> Asthmatic children aged 6–18 years with and without food allergy were treated with montelukast and placebo in a double-blind, placebo-controlled cross-over parallel-group study. The primary outcome of the study was improvement in FEV1%. Asthma control tests, spirometry and methacholine challenges were performed as well as Fractional Exhaled Nitric Oxide (FeNO) levels. PGD2, CystLT, and lipoxin levels were measured in exhaled breath condensate (EBC). <b><i>Results:</i></b> A total of 113 children were enrolled and 87 completed the study in accordance with the protocol. At baseline, children with food allergy and asthma (FAA) had higher levels of PGD2 and CysLT levels in the EBC than children with asthma alone (AA) (<i>p</i> &#x3c; 0.001 for each). In the montelukast arm, although FEV1% was significantly higher in the FAA group compared to AA (<i>p</i> = 0.005), this effect was linked to the baseline difference of FEV1% between both arms. Montelukast treatment failed to improve FEV1% in both groups compared to the placebo. No effect of montelukast was observed in the remaining study parameters. <b><i>Conclusion:</i></b> Although children with FAA do not show a more favorable response to montelukast treatment compared to AA, a significant difference between baseline PGD2 and CystLT levels between FAA and AA groups may point to a different endotype of childhood asthma.

Small molecules combined with narrowband UVB therapy for psoriasis patients

2020 ◽  
pp. 29-32
Author(s):  
A. A. Khotko ◽  
L. S. Kruglova
Keyword(s):  
Diabetes Mellitus ◽  
Body Weight ◽  
Small Molecules ◽  
Narrow Band ◽  
Clinical Manifestations ◽  
Comorbid Conditions ◽  
Combined Method ◽  
Narrowband Uvb ◽  
Increased Risk ◽  
Wide Range

Psoriasis is a heterogeneous disease characterized by a wide range of clinical manifestations. Patients with psoriasis and psoriatic arthritis have an increased risk of developing comorbid conditions, therefore, when prescribing therapy, it is necessary to take into account aspects of polypharmacy and the risks of developing infections. Apremilast is effective for the treatment of patients with psoriasis and comorbid comorbidity. To increase the effectiveness of apremilast therapy (achieving PASI 90 and PASI 100), it is possible to use a combination with narrow-band medium-wave phototherapy. The combined method allows achieving clear or almost clear skin in the vast majority of patients and is highly safe, as evidenced by the absence of severe side effects. The method is safe when used in patients with impaired glucose tolerance, diabetes mellitus, increased body weight and the risk of infections.

СОВРЕМЕННЫЕ ПУТИ ПОВЫШЕНИЯ ЭФФЕКТИВНОСТИ ТЕРАПИИ ПИЩЕВОЙ АЛЛЕРГИИ У ДЕТЕЙ

2019 ◽  
Author(s):  
V.A. Mukhortykh ◽  
V.A. Revyakina ◽  
I.A. Larkova ◽  
E.D. Kuvshinova
Keyword(s):  
Food Allergy ◽  
Adverse Reactions ◽  
Clinical Manifestations ◽  
Gastrointestinal Symptoms ◽  
Main Group ◽  
Food Allergies ◽  
Control Group ◽  
Complex Therapy ◽  
New Generation ◽  
Overall Effectiveness

Цель. Оценить эффективность и безопасность мультиштаммового пробиотика у детей с различными клиническими проявлениями пищевой аллергии. Материалы и методы. Под наблюдением находились 192 ребенка в возрасте от 3 мес до 3 лет с кожными, гастроинтестинальными и сочетанными (кожно-гастроинтестинальными) проявлениями пищевой аллергии. Пациенты основной группы получали комплексную терапию и мультиштаммовый пробиотик. Пациенты группы сравнения не получали исследуемый пробиотик. Поведена клиническая оценка динамики симптомов на фоне проводимого лечения (исходно и через 30 дней). Результаты. Использование мультиштаммового пробиотика в течение 30 дней у детей с различными клиническими проявлениями пищевой аллергии показало положительное влияние на общее состояние детей и динамику клинических симптомов со стороны кожи и желудочно-кишечного тракта. Общая эффективность терапии у детей основной группы составила 80,3 против 68,6 в группе сравнения. Переносимость пробиотика была хорошей, побочных реакций на прием не отмечено. Выводы. Включение пробиотика нового поколения в комплексную терапию пищевой аллергии способствует улучшению течения болезни и повышению эффективности лечения.Aim. To evaluate the effectiveness and safety of a multi-strain probiotic in children with various clinical manifestations of food allergy. Materials and methods. Under the supervision there were 192 children aged from 3 months to 3 years with skin, gastrointestinal and combined (skingastrointestinal) manifestations of food allergies. Patients of the main group received complex therapy and a multistrain probiotic. Patients in the control group did not receive probiotic. Clinical assessment of symptoms during the treatment was conducted (initially and after 30 days). Results. The use of a multistrain probiotic in children with various clinical manifestations of food allergy during 30 days showed improvement of skin and gastrointestinal symptoms of food allergy. The overall effectiveness of therapy in children of the main group was 80.3 versus 68.6 in the control group. Probiotic tolerance was good no adverse reactions were noted. Conclusion. The inclusion of a new generation probiotic in the complex therapy of food allergies helps to improve the course of the disease and increase the effectiveness of treatment.

Sign in / Sign up

Export Citation Format

Share Document